Prof Jonathan Heeney, of the University of Cambridge and DIOSVax, explains the unique technology behind his approach.
The biopharmaceutical company reports a year of strong revenue growth in 2019, but is braced for ‘unfavourable impact’ from Covid-19 epidemic.
Professor Jonathan Heeney, CEO of DIOSVax, says with the right resources it can move quickly.
The Cambridge Science Park-based company is transforming cell therapies with its technology.
The Cambridge Biomedical Campus company has also purchased the oncology product portfolio.
It has created a Simulated Cell platform capable of simulating hundreds of millions of experiments.
The Cambridge-based biopharmaceutical aims for its supply chain to be carbon negative by 2030.
The Babraham Research Campus company provides an alternative to animal testing using liver, heart, brain, pancreas and immunological cells.
CRUK suggests the molecule could offer improved anti-tumor activity with fewer side effects compared to antibody-based approaches.
A rival to CMR Surgical’s Versius, the SPORT system is focused on using single incisions.
